MARKET

PDSB

PDSB

PDS Biotechnology Corporation
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.36
+0.16
+1.74%
Opening 13:08 06/16 EDT
OPEN
9.31
PREV CLOSE
9.20
HIGH
10.38
LOW
9.30
VOLUME
1.88M
TURNOVER
--
52 WEEK HIGH
13.48
52 WEEK LOW
1.300
MARKET CAP
208.52M
P/E (TTM)
-13.1056
1D
5D
1M
3M
1Y
5Y
PDS Biotechnology Prices Common Stock Offering at $8.50 Per Share
MT Newswires · 13h ago
Mid-Afternoon Market Update: Nasdaq Down 100 Points; Clearside Biomedical Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded down 0.19% to 34,326.95 while the NASDAQ fell 0.70% to 14,074. The S&P also fell, dropping 0.12% to 4,249.99.
Benzinga · 22h ago
Is PDS Biotechnology Corporation (PDSB) A Good Stock To Buy?
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite ...
Insider Monkey · 1d ago
Mid-Day Market Update: Crude Oil Rises 1%; Sage Therapeutics Shares Slide
Midway through trading Tuesday, the Dow traded down 0.45% to 34,238.18 while the NASDAQ fell 0.53% to 14,099.27. The S&P also fell, dropping 0.25% to 4,244.45.
Benzinga · 1d ago
34 Stocks Moving In Tuesday's Mid-Day Session
Gainers HMG/Courtland Properties, Inc. (NYSE: HMG) shares surged 133% to $27.80.
Benzinga · 1d ago
Clearside Biomedical, Eloxx Pharmaceuticals leads healthcare gainers; PDS Biotechnology, Sage Therapeutics among major losers
Gainers: Clearside Biomedical (CLSD) +30%, Eloxx Pharmaceuticals (ELOX) +15%, Fusion Pharmaceuticals (FUSN) +14%, Precipio (PRPO) +14%, Ocugen (OCGN) +11%.Losers: PDS Biotechnology (PDSB) -27%, Sage Therapeutics (SAGE) -16%, NeuroBo Pharmaceuticals (NRBO) ...
Seekingalpha · 1d ago
PDS Biotechnology Shares Drop 25% After Public Offering Prices
marketwatch.com · 1d ago
Mid-Morning Market Update: Markets Open Lower; US Retail Sales Drop 1.3% In May
Following the market opening Tuesday, the Dow traded down 0.34% to 34,275.92 while the NASDAQ fell 0.09% to 14,161.73. The S&P also fell, dropping 0.10% to 4,250.89.
Benzinga · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PDSB. Analyze the recent business situations of PDS Biotechnology Corporation through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PDSB stock price target is 17.00 with a high estimate of 25.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 49
Institutional Holdings: 8.14M
% Owned: 36.55%
Shares Outstanding: 22.28M
TypeInstitutionsShares
Increased
7
237.90K
New
12
559.53K
Decreased
7
251.04K
Sold Out
9
550.51K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.43%
Pharmaceuticals & Medical Research
+0.06%
Key Executives
Non-Executive Chairman/Independent Director
Stephen Glover
President/Chief Executive Officer/Director
Frank Bedu-Addo
Chief Financial Officer/Chief Accounting Officer
Seth Van Voorhees
Chief Scientific Officer
Gregory Conn
Other
Lauren Wood
Director
Ilian Iliev
Independent Director
Kamil Ali-Jackson
Independent Director
DeLyle Bloomquist
Independent Director
Otis Brawley
Independent Director
Gregory Freitag
Independent Director
Richard Sykes
No Data
About PDSB
PDS Biotechnology Corp, formerly Edge Therapeutics, Inc., is an immuno-oncology company, The Company is focused on developing a pipeline of clinical-stage immunotherapies. Its therapies are developed for the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Versamune is its synthetic lipid-based immunotherapy platform. Its lead product candidate, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. Its pipeline also includes PDS0102, PDS0103 and PDS0104. Its pipeline of Versamune-based products are all administered by subcutaneous injection .DS0102 is being developed for the treatment of prostate and breast cancers. PDS0103 is based on novel agonist antigens of the mucin-1 (MUC-1) oncogenic C-terminal region. PDS0104 is being developed for the treatment of melanoma.

Webull offers kinds of PDS Biotechnology Corp stock information, including NASDAQ:PDSB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PDSB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PDSB stock methods without spending real money on the virtual paper trading platform.